Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04910165 · ClinicalTrials.gov registry record · Phase 3
Exparel Use in Adductor Canal Block After Total Knee Arthroplasty
A Phase 3 study, sponsored by St. Luke's Hospital, Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT04910165 is a Phase 3 study that has completed, run by St. Luke's Hospital, Pennsylvania. The registered enrollment target is 100 participants.
The verdict
NCT04910165, a Phase 3 study, has completed, sponsored by St. Luke's Hospital, Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal Blocks for peri-operative pain control following a total knee arthroplasty (TKA) procedure.
Interventions
- DRUG Exparel
- DRUG Ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2021-10-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04910165
The ClinicalTrials.gov registry entry for NCT04910165 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Luke's Hospital, Pennsylvania, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exparel is the first listed.
NCT04910165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04910165 about?
NCT04910165 is a clinical study titled "Exparel Use in Adductor Canal Block After Total Knee Arthroplasty". Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal Blocks for peri-operativ...
What is the current status of trial NCT04910165?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2020-06-01. Estimated completion is 2021-10-15.
What interventions are being tested in trial NCT04910165?
The interventions under investigation include: Exparel (DRUG), Ropivacaine (DRUG).
Who is sponsoring clinical trial NCT04910165?
This trial is sponsored by St. Luke's Hospital, Pennsylvania, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.